Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: = .003). In contrast, MRD-positive patients assigned to clofarabine (vs high-dose cytarabine) consolidation had significantly inferior OS. Clofarabine is inferior to standard intensive therapy despite similar remission rates. Achieving MRD-negative remission is associated with high, sustained rates of OS regardless of therapy. Increasing MRD negativity and improving outcomes among MRD-positive patients remain pressing, ongoing challenges. This trial was registered at www.clinicaltrials.gov as NCT02085408.
Source: Blood Neoplasia
Authors: James M. Foran, Zhuoxin Sun, Selina M. Luger, David F. Claxton, Hillard M. Lazarus, Daniel A. Arber, Jacob M. Rowe, Elisabeth Paietta, Janis Racevskis, Fran Garrett-Bakelman, Yanming Zhang, Jessica K. Altman, Aref Al-Kali, Hong Zheng, Keith W. Pratz, E. Randolph Broun, Bayard L. Powell, Kristen Marie O’Dwyer, John E. Godwin, Yishai Ofran, Mark R. Litzow, Martin S. Tallman
Institutions: Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida), Dana-Farber Cancer Institute, Abramson Cancer Center, University of Pennsylvania, Penn State Cancer Institute, Penn State Milton S. Hershey Medical Center, University Hospitals of Cleveland, University Hospitals Cleveland Medical Center, Case Western Reserve University, University of Chicago, Shaare Zedek Medical Center, Bikur Cholim Hospital, Montefiore Medical Center, University of Virginia Medical Center, University of Virginia Cancer Center, University of Virginia, Memorial Sloan Kettering Cancer Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Mayo Clinic, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Jewish Hospital, Wake Forest University Health Sciences, Wake Forest University, Providence Portland Medical Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,000
Awards: ECOG-ACRIN Network Group Operations Center, MINORITY-BASED COMMUNITY ONCOLOGY PROGRAM, Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer Center, G4613367208, Johns Hopkins University NCTN Lead Academic Site Program, Alliance for Clinical Trials in Oncology Operations Center, G9000012443, G9000030791, G9000097678, G9000273481, G9000280145, G9000327439, G9000339569
OpenAlex ID: W7124164980